BioNxt Solutions Secures Key Patent Protection Across Eurasian Markets

BioNxt Solutions has achieved a significant milestone in its commercial strategy. The biotechnology firm has been granted exclusive rights to its sublingual drug delivery technology by the Eurasian Patent Organization, providing market protection for the next 18 years. This development opens access to a consumer base of approximately 200 million people across multiple countries.

Patent number 051510, officially issued on November 14, 2025, provides BioNxt Solutions with exclusive commercialization rights across all eight EAPO member states, including Russia, Kazakhstan, and Belarus. The protected technology covers sublingual administration methods for cancer therapeutics, with particular focus on the company’s proprietary Cladribine thin-film formulation. With protection extending until June 14, 2043, the company establishes both long-term competitive insulation and enhanced leverage Read more...